AIM IMMUNOTECH INC.
Income Statement
| Line Item | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $50.0K | $40.0K | $65.0K | $46.0K | $42.0K | $49.0K | $57.0K | $21.0K |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $1.1M | $2.0M | $3.2M | $2.7M | $3.0M | $2.1M | $2.1M | $1.4M |
| SG&A Expense | $2.6M | $3.8M | $10.9M | $5.4M | $2.6M | $2.3M | $3.7M | $5.2M |
| Operating Income | $-3.7M | $-5.7M | $-14.0M | $-8.2M | $-5.5M | $-4.3M | $-5.6M | $-6.5M |
| Operating Margin | -7,388.0% | -14,335.0% | -21,543.1% | -17,732.6% | -13,002.4% | -8,765.3% | -9,745.6% | -31,052.4% |
| Interest Expense | $179.0K | $72.0K | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-1.8M | $-5.8M | $-12.6M | $-7.8M | $-4.9M | $-3.7M | $-4.4M | $-6.4M |
| Net Margin | -3,672.0% | -14,542.5% | -19,347.7% | -16,991.3% | -11,688.1% | -7,471.4% | -7,700.0% | -30,404.8% |
| EPS (Basic) | $-1.00 | $-0.04 | $-0.09 | $-0.05 | $-0.03 | $-0.03 | $-0.03 | $-0.04 |
| EPS (Diluted) | $-1.00 | $-0.04 | $-0.09 | $-0.05 | $-0.03 | $-0.03 | — | $-0.04 |
| Shares Outstanding (Basic) | 158.5M | 148.4M | 145.8M | 145.9M | 145.2M | 145.2M | 144.3M | — |
| Shares Outstanding (Diluted) | 158.5M | 148.4M | 145.8M | 145.9M | 145.2M | 145.2M | 144.3M | 144.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |